Xencor (XNCR) Cash & Current Investments (2013 - 2026)
Xencor's (XNCR) quarterly Cash & Current Investments came in at $384.4 million in Q1 2026, up 334.1% year-on-year from $88.5 million in Q1 2025, and down 11.68% on a QoQ basis from $435.2 million in Q4 2025.
Xencor (XNCR) Cash & Current Investments (2013 - 2026) Analysis & Trends
Xencor (XNCR) has 14 years of Cash & Current Investments data on file, last reported at $384.4 million in Q1 2026.
- On a quarterly basis, Cash & Current Investments rose 334.1% year-over-year to $384.4 million in Q1 2026; TTM through Mar 2026 was $384.4 million, a 334.1% increase from a year earlier, with the FY2025 full-year figure at $435.2 million, down 3.25% from the prior year.
- Cash & Current Investments for Q1 2026 stood at $384.4 million, down from $435.2 million in the prior quarter.
- Over the last five years, Cash & Current Investments for XNCR reached as high as $551.5 million in Q4 2023 and fell as low as $59.0 million in Q2 2024.
- Historically, Cash & Current Investments has averaged $238.0 million across 5 years, with a median of $112.1 million in 2023.
- Across the five-year window, Cash & Current Investments tumbled 79.54% in 2022 and jumped 583.32% in 2025, its largest moves.
- Year by year, Cash & Current Investments stood at $96.4 million in 2022, then surged by 472.27% to $551.5 million in 2023, then declined by 18.43% to $449.8 million in 2024, then slipped by 3.25% to $435.2 million in 2025, then decreased by 11.68% to $384.4 million in 2026.
- Per Business Quant data, the three most recent Cash & Current Investments figures were $384.4 million in Q1 2026, $435.2 million in Q4 2025, and $112.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 283.54 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 8.75 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 5.18 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Xencor | 1.49 Bn | 1.11 Bn | - | 384.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 384.38 Mn |
| Dec 31, 2025 | 435.23 Mn |
| Sep 30, 2025 | 112.55 Mn |
| Jun 30, 2025 | 403.43 Mn |
| Mar 31, 2025 | 88.55 Mn |
| Dec 31, 2024 | 449.85 Mn |
| Sep 30, 2024 | 464.07 Mn |
| Jun 30, 2024 | 59.04 Mn |
| Mar 31, 2024 | 75.57 Mn |
| Dec 31, 2023 | 551.52 Mn |
| Sep 30, 2023 | 465.56 Mn |
| Jun 30, 2023 | 74.71 Mn |
| Mar 31, 2023 | 112.10 Mn |
| Dec 31, 2022 | 96.37 Mn |
| Sep 30, 2022 | 84.84 Mn |
| Jun 30, 2022 | 76.30 Mn |
| Mar 31, 2022 | 111.70 Mn |
| Dec 31, 2021 | 180.34 Mn |
| Sep 30, 2021 | 88.78 Mn |
| Jun 30, 2021 | 161.07 Mn |